Buscar
Immunoprecise Antibodies Ltd
IPAAñadir a la lista de seguimiento
2.070USD
0.0000.00%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
95.54MCap. mercado
PérdidaP/E TTM
Más Datos de Immunoprecise Antibodies Ltd Compañía
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
Información de Immunoprecise Antibodies Ltd
Símbolo de cotizaciónIPA
Nombre de la empresaImmunoprecise Antibodies Ltd
Fecha de salida a bolsaJan 30, 1987
Director ejecutivoDr. Jennifer Lynne Bath, Ph.D.
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 30
DirecciónIndustrious 823 Congress Ave Suite 300
CiudadAUSTIN
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal78701
Teléfono16048060626
Sitio Webhttps://www.ipatherapeutics.com/
Símbolo de cotizaciónIPA
Fecha de salida a bolsaJan 30, 1987
Director ejecutivoDr. Jennifer Lynne Bath, Ph.D.
Ejecutivos de Immunoprecise Antibodies Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jennifer Lynne Bath, Ph.D.
Dr. Jennifer Lynne Bath, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
498.12K
--
Dr. Kamil Isaev
Dr. Kamil Isaev
Independent Director
Independent Director
3.19K
--
Mr. Dirk Witters
Mr. Dirk Witters
Independent Director
Independent Director
1.95K
--
Ms. Kari Graber
Ms. Kari Graber
Vice President - Commercial Services
Vice President - Commercial Services
700.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Director
Director
--
--
Mr. Joseph Scheffler
Mr. Joseph Scheffler
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Shuji Sato
Dr. Shuji Sato
Vice President - Innovative Solutions
Vice President - Innovative Solutions
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jennifer Lynne Bath, Ph.D.
Dr. Jennifer Lynne Bath, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
498.12K
--
Dr. Kamil Isaev
Dr. Kamil Isaev
Independent Director
Independent Director
3.19K
--
Mr. Dirk Witters
Mr. Dirk Witters
Independent Director
Independent Director
1.95K
--
Ms. Kari Graber
Ms. Kari Graber
Vice President - Commercial Services
Vice President - Commercial Services
700.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Director
Director
--
--
Mr. Joseph Scheffler
Mr. Joseph Scheffler
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Immunoprecise Antibodies Ltd?
Los cinco principales accionistas de Immunoprecise Antibodies Ltd son: Dr. Jennifer Lynne Bath, Ph.D.
¿Cuántas instituciones poseen acciones de Immunoprecise Antibodies Ltd (IPA)?
A fecha de 2026Q1, 47 instituciones poseen acciones de Immunoprecise Antibodies Ltd, con un valor de mercado combinado de aproximadamente 4.54M, lo que representa el 9.73% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 212280.00.
¿Cuál es la mayor fuente de ganancias de Immunoprecise Antibodies Ltd?
El 2026Q1, el segmento empresarial Project revenue generó la ganancia más alta para Immunoprecise Antibodies Ltd, ascendiendo a 4.11M y representando el 98.85% de la ganancia total.